The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNFα biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.
Legal claims defining the scope of protection. Each claim is shown in both the original legal language and a plain English translation.
2. The method of claim 1, wherein the subject is determined to suffer from cognitive impairment for having a lower score in at least one neurocognitive evaluation selected from the group consisting of a clock drawing test, verbal fluency test, trail making test, list learning test, sleep disturbances, visual hallucinations, behavioral disturbances, motor disturbances, and any combinations thereof, as compared to a normal subject.
This invention relates to methods for assessing cognitive impairment in a subject by evaluating performance in specific neurocognitive tests. The method involves comparing the subject's scores in at least one of several standardized neurocognitive evaluations to those of a normal subject. The evaluations include a clock drawing test, verbal fluency test, trail making test, list learning test, and assessments of sleep disturbances, visual hallucinations, behavioral disturbances, and motor disturbances. A lower score in any of these tests indicates cognitive impairment. The method may also involve analyzing combinations of these evaluations to determine the presence and severity of cognitive decline. The approach aims to provide a comprehensive assessment by incorporating multiple cognitive and behavioral metrics, allowing for a more nuanced diagnosis of cognitive impairment compared to single-test evaluations. The invention is particularly useful in clinical settings where early detection of cognitive decline is critical for intervention and treatment planning.
3. The method of claim 1, wherein the blood sample is a serum or a plasma sample.
The invention relates to a method for analyzing blood samples, specifically serum or plasma samples, to detect or quantify a target analyte. The method involves preparing the blood sample by separating serum or plasma from whole blood, then processing the sample to isolate or concentrate the target analyte. This may include steps such as centrifugation, filtration, or chemical treatment to remove interfering substances. The processed sample is then subjected to a detection technique, such as spectroscopy, immunoassay, or molecular analysis, to measure the presence or concentration of the target analyte. The method may also include calibration steps to ensure accuracy, such as comparing the sample to a reference standard. The technique is designed to improve sensitivity and specificity in diagnostic testing, particularly for clinical or research applications where precise analyte detection is critical. The use of serum or plasma ensures compatibility with common blood processing techniques and minimizes variability in results. The method may be automated or performed manually, depending on the application.
6. The method of claim 5, wherein the subject is determined to suffer from cognitive impairment for having a lower score in at least one neurocognitive evaluation selected from the group consisting of clock drawing test, verbal fluency test, trail making test, list learning test, sleep disturbances, visual hallucinations, behavioral disturbances, motor disturbances, and any combinations thereof, as compared to a normal subject.
This invention relates to methods for assessing cognitive impairment in a subject by evaluating performance in specific neurocognitive tests. The method involves comparing a subject's scores in at least one neurocognitive evaluation to those of a normal subject to determine the presence of cognitive impairment. The evaluations include the clock drawing test, verbal fluency test, trail making test, list learning test, sleep disturbances, visual hallucinations, behavioral disturbances, motor disturbances, or any combination thereof. A lower score in any of these evaluations compared to a normal subject indicates cognitive impairment. The method provides a standardized approach to identifying cognitive deficits by leveraging multiple assessment tools, ensuring comprehensive evaluation. This technique is useful in clinical settings for early detection and monitoring of cognitive disorders, enabling timely intervention and treatment planning. The inclusion of diverse tests allows for a holistic assessment, capturing various aspects of cognitive function, from memory and executive function to motor and behavioral symptoms. The method supports differential diagnosis by distinguishing between normal aging and pathological cognitive decline.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
July 9, 2014
December 13, 2022
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.